Mechanisms of sulfonylurea's stimulation of insulin secretion in vivo - Selective amplification of insulin secretory burst mass

被引:35
作者
Porksen, NK
Munn, SR
Steers, JL
Schmitz, O
Veldhuis, JD
Butler, PC
机构
[1] MAYO CLIN, ENDOCRINE RES UNIT, ROCHESTER, MI USA
[2] MAYO CLIN, DIV TRANSPLANT SURG, ROCHESTER, MI USA
[3] NATL SCI FDN, CTR BIOL TIMING, CHARLOTTESVILLE, VA USA
[4] UNIV VIRGINIA, DEPT MED, CHARLOTTESVILLE, VA USA
[5] AARHUS KOMMUNE HOSP, DEPT MED, DK-8000 AARHUS, DENMARK
关键词
D O I
10.2337/diabetes.45.12.1792
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although sulfonylureas enhance insulin secretion, it is unknown whether these hypoglycemic chemicals stimulate insulin secretion through the augmentation of the pulsatile or basal modes of insulin release, Enhanced pulsatile insulin could occur in turn through amplification of the burst mass or an increase in burst frequency. To address the mechanism of sulfonylurea action, we employed a recently validated canine model with a portal vein sampling catheter and flow probe to measure pulsatile insulin secretion in vivo directly in response to tolbutamide infusion or ingestion. After a 16-h fast, seven dogs were studied in the postabsorptive basal state and during a tolbutamide (0.2 mg/min) infusion when their plasma glucose concentrations were clamped at euglycemia. Insulin concentrations in the carotid artery (basal vs. tolbutamide, 85 +/- 12 vs. 325 +/- 66 pmol/l; P < 0.01) and portal vein (basal vs. tolbutamide, 345 +/- 55 vs. 1,288 +/- 230 pmol/l; P < 0.01) increased during tolbutamide infusion, but the portal vein plasma flow did not change, Increased plasma insulin concentrations were achieved by a fourfold increase in the total insulin secretion rate (2.3 +/- 0.2 to 9.4 +/- 1.9 pmol . kg(-1) . min(-1); basal vs. tolbutamide, P < 0.01). The augmented total insulin secretion was achieved mechanistically via a marked and selective increase in the insulin secretory burst mass (basal vs, tolbutamide, 266 +/- 64 vs. 817 +/- 144 pmol/pulse; P < 0.01), with no change in portal-vein insulin pulse frequency (basal vs. tolbutamide, 10.1 +/- 0.6 vs. 11.1 +/- 0.8 pulses/h; P = 0.3). Oral (250 mg) tolbutamide also magnified the endogenous insulin secretion rate by the preferential amplification of the secretory pulse mass (basal vs. tolbutamide, 167 +/- 37 vs. 362 +/- 50 pmol/pulse; P < 0.01). Neither the infusion nor the ingestion of tolbutamide changed the calculated clearance rates of endogenously secreted insulin. We conclude that sulfonylurea (tolbutamide) induced insulin secretion in vivo is achieved by the highly selective amplification of insulin secretory burst mass with no change in basal insulin release or the frequency of the beta-cell-network pacemaker.
引用
收藏
页码:1792 / 1797
页数:6
相关论文
共 28 条
[1]   INFLUENCE OF SULFONYLUREAS ON THE SECRETION, DISPOSAL AND EFFECT OF INSULIN [J].
ALMER, LO ;
JOHANSSON, E ;
MELANDER, A ;
WAHLINBOLL, E .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (01) :27-32
[2]  
BOYD AE, 1991, RECENT PROG HORM RES, V47, P299
[3]   A NEW ANTI-DIABETIC PRINCIPLE [J].
FRANKE, H ;
FUCHS, J .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1955, 80 (40) :1449-1452
[4]  
GERICH JE, 1989, NEW ENGL J MED, V321, P1231
[5]   INSULIN, GLUCAGON, AND GLUCOSE EXHIBIT SYNCHRONOUS, SUSTAINED OSCILLATIONS IN FASTING MONKEYS [J].
GOODNER, CJ ;
WALIKE, BC ;
KOERKER, DJ ;
ENSINCK, JW ;
BROWN, AC ;
CHIDECKEL, EW ;
PALMER, J ;
KALNASY, L .
SCIENCE, 1977, 195 (4274) :177-179
[6]  
GRODSKY GM, 1977, FED PROC, V36, P2714
[7]  
GROOP L, 1987, DIABETES CARE, V10, P71
[8]   CYCLIC OSCILLATIONS OF BASAL PLASMA-GLUCOSE AND INSULIN CONCENTRATIONS IN HUMAN-BEINGS [J].
LANG, DA ;
MATTHEWS, DR ;
PETO, J ;
TURNER, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (19) :1023-1027
[9]   BRIEF, IRREGULAR OSCILLATIONS OF BASAL PLASMA-INSULIN AND GLUCOSE-CONCENTRATIONS IN DIABETIC MAN [J].
LANG, DA ;
MATTHEWS, DR ;
BURNETT, M ;
TURNER, RC .
DIABETES, 1981, 30 (05) :435-439
[10]  
LEWIS GF, 1994, J CLIN ENDOCR METAB, V78, P66